Tracking head and neck cancer recurrence with liquid biopsies
A simple blood draw that reveals whether cancer has returned sounds almost too good to be true, yet that is precisely the promise behind liquid biopsy technology. For patients treated for head and neck cancers, the months and years after surgery or radiotherapy are filled with anxiety as they wait for scan results. Researchers in Brisbane and across Queensland are exploring how circulating tumour DNA and other blood-based biomarkers might one day detect microscopic disease long before it shows up on imaging.
Head and neck cancers account for a meaningful share of new cancer diagnoses in Australia, with HPV-related oropharyngeal cancers climbing sharply over the past two decades. Survivors face some of the highest recurrence rates of any solid tumour, and traditional follow-up relies on a mix of imaging, endoscopy, and clinical examination that can miss early disease. The prospect of a routine blood test that flags molecular residual disease has captured the attention of clinicians, researchers, and consumer advocacy groups from Cairns to the Gold Coast.
How liquid biopsy technology works
A liquid biopsy captures fragments of DNA, RNA, or other molecules that tumours shed into the bloodstream. In head and neck cancer, the most studied target is circulating tumour DNA, often abbreviated as ctDNA, which carries the same mutations found in the original tumour. A laboratory can identify these mutations using highly sensitive techniques such as next-generation sequencing or droplet digital polymerase chain reaction, allowing clinicians to track disease burden over time without repeating invasive tissue biopsies.
The approach is not limited to DNA. Researchers are also investigating circulating microRNAs, tumour-educated platelets, and exosomes as complementary signals. Each biomarker class has its own strengths and limitations, and a growing body of evidence suggests that combining several analytes may improve sensitivity for detecting minimal residual disease. For patients in regional Queensland who travel hours to reach a tertiary cancer centre, the appeal of a blood test that can be collected locally and posted to a central laboratory is hard to overstate.
Why surveillance matters after treatment
Recurrence in head and neck cancer often carries a poor prognosis, particularly when disease has spread to distant sites. Salvage surgery is possible in some cases, but it is most effective when the tumour is caught early. Conventional surveillance schedules typically involve imaging every three to six months during the first two years, an approach that exposes patients to repeated radiation and significant cost while still leaving gaps where fast-growing disease can escape detection.
Liquid biopsies address this gap by sampling the tumour genome continuously rather than at fixed intervals. A landmark study published recently demonstrated that ctDNA-based surveillance identified molecular recurrence in HPV-positive oropharyngeal cancer patients a median of four months ahead of clinical detection. Australian researchers at QIMR Berghofer and the University of Queensland have been contributing to similar international efforts, helping to refine which mutation panels work best for our diverse patient population.
Clinical trials across Australian centres
Several Australian sites are now participating in trials that embed liquid biopsy sampling into standard follow-up pathways. The translational research funding landscape has shifted considerably, with the Medical Research Future Fund and the National Health and Medical Research Council backing projects that bridge laboratory discovery and bedside care. Queensland-led consortia are evaluating several promising strategies:
- Whether ctDNA clearance during chemoradiation can serve as an early indicator of treatment success
- How methylation patterns in cell-free DNA might distinguish true recurrence from transient shedding
- Whether ultra-sensitive assays can overcome the relatively low ctDNA levels seen in HPV-positive disease
- How serial sampling intervals should be spaced to balance sensitivity with patient convenience
HPV-positive oropharyngeal cancer, which disproportionately affects younger Australian men, has become a particular focus of these efforts. Researchers are also exploring whether ctDNA dynamics can help stratify patients for de-escalation trials, sparing some from the most intensive treatment regimens.
Barriers to routine clinical use
Real-world implementation faces several hurdles. Standardising pre-analytical variables such as blood collection tubes, transport conditions, and processing times is essential for reliable results, yet many hospital networks lack the infrastructure to guarantee consistency. Reimbursement through Medicare remains uncertain, and without a clear billing pathway, public hospital laboratories may struggle to justify the upfront investment in sequencing platforms and bioinformatics pipelines.
There are also clinical interpretation challenges. A positive ctDNA result months before clinical recurrence does not always lead to actionable findings, and oncologists must weigh the psychological burden of molecular surveillance against uncertain benefit. Patients who have already endured surgery, radiotherapy, and chemotherapy may find that knowing microscopic disease is present, without an immediate curative option, adds a layer of distress. Frameworks such as psychological support frameworks offer clinicians a structured way to support patients through this kind of uncertainty.
Equity and access in diverse communities
Australia's multicultural population and the geographic spread of head and neck cancer make equitable access a pressing concern. Indigenous Australians experience higher incidence of certain head and neck subsites, often present with advanced disease, and may live far from specialist cancer centres in places like Townsville or Mount Isa. Liquid biopsy sampling, if rolled out thoughtfully, could reduce the burden of travel by enabling local collection and remote analysis, but only if collection points are established in primary care and Aboriginal Community Controlled Health Organisations.
Community-based models of care offer useful templates. The role that community pharmacy partnerships play in managing chronic conditions in Indigenous communities demonstrates how trusted local providers can extend the reach of specialist services. Embedding liquid biopsy collection within similar networks would require careful co-design with community leaders, alongside culturally safe communication about what a positive result might mean.
Practical considerations for patients and clinicians
For clinicians thinking about introducing liquid biopsy into their own practice, several practical questions deserve attention:
- Confirm that the assay offered by the laboratory has been validated for the specific head and neck subsite being monitored, since sensitivity varies by tumour type
- Establish clear protocols for how results will be communicated, including thresholds for action and pathways for further imaging or biopsy
- Discuss the limits of the test openly with patients, including the possibility of false negatives during very low disease burden windows
- Build referral links with psychosocial support services before introducing molecular surveillance, rather than after a difficult result
For patients, the key is to ask questions and remain informed. Survivorship care plans should outline the schedule of imaging, clinical review, and any blood-based monitoring being offered, along with contact details for the treating team.
A path forward for Queensland
The next five years will likely determine whether liquid biopsies become standard of care or remain a research tool in head and neck cancer. Investment in Australian-led trials, harmonised laboratory standards, and consumer engagement will shape that trajectory. Brisbane Diamantina Health Partners is well placed to coordinate this work, drawing on its network of research institutes, universities, and health services across the region.
If you are a clinician, researcher, or consumer representative interested in shaping the future of molecular surveillance, we encourage you to connect with the Brisbane Diamantina Health Partners team and explore opportunities for collaboration and ongoing research updates.
